Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Brainsway Ltd is a diagnostics & research business based in the US. Brainsway shares (BWAY) are listed on the NASDAQ and all prices are listed in US Dollars. Brainsway employs 107 staff and has a trailing 12-month revenue of around USD$21.3 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$7.54 |
---|---|
52-week range | USD$5.1 - USD$12.53 |
50-day moving average | USD$6.186 |
200-day moving average | USD$6.2209 |
Wall St. target price | USD$11.19 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.028 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.54 from 2020-12-31
1 week (2021-01-09) | N/A |
---|---|
1 month (2020-12-18) | 22.20% |
3 months (2020-10-16) | 25.46% |
6 months (2020-07-17) | 30.68% |
1 year (2020-01-17) | -35.61% |
---|---|
2 years (2019-01-16) | N/A |
3 years (2018-01-16) | N/A |
5 years (2016-01-16) | N/A |
Revenue TTM | USD$21.3 million |
---|---|
Gross profit TTM | USD$19.2 million |
Return on assets TTM | -8.68% |
Return on equity TTM | -31.6% |
Profit margin | -34.28% |
Book value | $1.65 |
Market capitalisation | USD$68.3 million |
TTM: trailing 12 months
There are currently 495 Brainsway shares held short by investors – that's known as Brainsway's "short interest". This figure is 12.9% down from 568 last month.
There are a few different ways that this level of interest in shorting Brainsway shares can be evaluated.
Brainsway's "short interest ratio" (SIR) is the quantity of Brainsway shares currently shorted divided by the average quantity of Brainsway shares traded daily (recently around 16500). Brainsway's SIR currently stands at 0.03. In other words for every 100,000 Brainsway shares traded daily on the market, roughly 30 shares are currently held short.
However Brainsway's short interest can also be evaluated against the total number of Brainsway shares, or, against the total number of tradable Brainsway shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Brainsway's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Brainsway shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Brainsway shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Brainsway.
Find out more about how you can short Brainsway stock.
We're not expecting Brainsway to pay a dividend over the next 12 months.
Over the last 12 months, Brainsway's shares have ranged in value from as little as $5.1 up to $12.53. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainsway's is 0.6265. This would suggest that Brainsway's shares are less volatile than average (for this exchange).
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.